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Abstract Class I Histone deacetylases (HDACs) play a
central role in controlling cell cycle regulation, cell differ-
entiation, and tissue development. These enzymes exert
their function by deacetylating histones and a growing
number of non-histone proteins, thereby regulating gene
expression and several other cellular processes. Class I
HDACs comprise four members: HDAC1, 2, 3, and 8.
Deletion and/or overexpression of these enzymes in mam-
malian systems has provided important insights about their
functions and mechanisms of action which are reviewed
here. In particular, unique as well as redundant functions
have been identified in several paradigms. Studies with
small molecule inhibitors of HDACs have demonstrated the
medical relevance of these enzymes and their potential as
therapeutic targets in cancer and other pathological condi-
tions. Going forward, better understanding the specific role
of individual HDACs in normal physiology as well as in
pathological settings will be crucial to exploit this protein
family as a useful therapeutic target in a range of diseases.
Further dissection of the pathways they impinge on and of
their targets, in chromatin or otherwise, will form important
avenues of research for the future.
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Introduction
Acetylation of histones is a dynamic process controlled by
two families of enzymes: histone acetyl transferases
(HATs) and histone deacetylases (HDACs). HATs catalyze
the transfer of an acetyl group to lysine residues of histone
tails, thereby neutralizing the positive charge of histones.
This change decreases the affinity between DNA and his-
tones and relaxes chromatin structure, making it more
accessible for transcription factors. Acetylated histones also
act as docking sites for transcription factors carrying a
bromodomain [1]. Therefore, HATs are considered as
transcription co-activators. The activity of HATs is bal-
anced by the HDACs that deacetylate histone tails, promote
chromatin compaction, and act as co-repressors. In addition
to histones, HDACs can deacetylate non-histone proteins
such as transcription factors and a growing number of other
proteins [2, 3]. As a result, HDACs are now also called
KDACs, or lysine deacetylases [4]. Recently, mass spec-
trometric analysis identified several thousand acetylation
sites in HeLa cells, a large fraction of which was altered
upon treatment of cells with HDAC inhibitors (HDACis)
[3]. The large number of potential HDACs substrates sug-
gests that these enzymes may play diverse functions in
many cellular processes beyond the regulation of gene
expression. Many of the early investigations on HDACs
function have been based on HDACis and their effect on
tumor cell proliferation, in particular induction of cell cycle
arrest and apoptosis. Although these initial studies demon-
strated the important role of HDACs in cell cycle
regulation, the specific role of individual members of the
HDAC family has only recently been addressed genetically.
Several recent studies based on deletion and/or overex-
pression of specific HDACs have highlighted the complex
network of cellular processes that involve HDACs action.
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In this review, we will focus on the role of class I
HDACs in cell cycle regulation, cell differentiation, and
tissue development in mammalian systems. We first briefly
describe the properties of the class I members and their
multisubunit complexes. Then, we describe the phenotypes
linked to the deletion or overexpression of these enzymes
in mammalian systems and the molecular mechanisms
involved in their function. Finally, we discuss the effects of
HDACis as promising anti-cancer drugs.
Protein deacetylases
The mammalian genomes encode 18 enzymes with deace-
tylase activity which comprise two distinct groups: classical
HDACs, whose enzymatic activity requires Zn2?, and sir-
tuins, which are NAD?-dependent. The classical HDAC
family contains 11 members divided into four classes. Class
I contains HDAC1, 2, 3, and 8, class IIa comprises HDAC4,
5, 7, and 9, class IIb includes HDAC6 and 10, and class IV
comprises the unique member HDAC11 (Fig. 1).
The sirtuin enzymes are generally classified as class III
HDACs. This family contains seven members, SIRT1–
SIRT7 which are organized into four classes. Sirtuin class I
contains SIRT1, 2, and 3. SIRT4 and SIRT5 constitute
class II and III, respectively, and class IV comprises SIRT6
and SIRT7. Sirtuins are involved in many biological pro-
cesses including genome stability, cell cycle regulation and
play critical roles in several metabolic pathways (for
review, see [5]). The reader is referred to several excellent
reviews discussing the classification and regulation of the
different HDACs [6, 7]. Here, we focus on summarizing
what is known about class I HDACs, and, in particular,
what has been learned from their genetic analysis in higher
eukaryotes.
Class I HDACs complexes and their function
in mammals
HDACs lack a DNA-binding motif and require interaction
with other proteins to be recruited to their chromatin tar-
gets. Class I HDACs, except HDAC8, are found as subunits
of several multisubunit complexes and interact with vari-
ous transcription factors. Mammalian HDAC1 and 2
originated from a common ancestor via gene duplication
[8]. They exhibit high sequence homology, having 87%
amino acid identity in mice (Fig. 1), and their C-terminal
tail contains tandem casein kinase-2 (CK2) phosphoryla-
tion sites [9]. HDAC3 shares the homologous catalytic
domain with HDAC1 and 2, but has only one CK2 phos-
phorylation site [10]. HDAC8 has a conserved motif for
protein kinase A phosphorylation [8, 11]. HDAC1 and 2
form a heterodimer and constitute the catalytic core of the
Sin3, NuRD, and CoREST complexes, while HDAC3 is a
subunit of the N-CoR/SMRT complex (Fig. 2). Class I
HDAC-containing complexes may have different subunits
in different cell types, at specific developmental stages or
depending on the purification methods (for reviews, see [4,
12, 13]).
In mammals, class I HDACs are ubiquitously expressed
suggesting a general role in transcription repression.
However, deletion of these enzymes individually leads to
deregulation of a limited set of genes, indicating a specific
role of class I HDACs in transcription regulation [14, 15].
Furthermore, class I HDACs interact with many lineage-
specific transcription factors suggesting that these enzymes
may play an important role in controlling specific tran-
scriptional programs. The majority of recent findings about
the role of class I HDACs come from studies based on
deletion or overexpression of these enzymes in mammalian
systems. In the following section, we will discuss the
phenotypes linked to the deregulation of class I HDACs
expression with emphasis on knockout (KO) mouse mod-
els, either globally or in a tissue-specific manner. We will
also discuss the molecular mechanisms involved in HDACs
action.
Germline deletion of class I HDACs
Every class I HDAC has been deleted either globally or in a
tissue-specific manner in the mouse (see Table 1). Germ-
line deletion of HDAC1 in mice leads to early embryonic
lethality before E9.5 due to severe proliferation defects and
retardation in development [16]. In contrast to the clear
effect of HDAC1 global deletion, the impact of HDAC2
ablation in mice varies depending on the genetic approach
used. Indeed, independent studies investigating the effect
of HDAC2 ablation in mice reported somewhat divergent
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Fig. 1 HDAC classification. The HDAC classes are indicated (class
III HDACs—sirtuins—are not depicted). Blue rectangles depict the
Deacetylase Domain (DAC), red rectangles indicate phosphorylation
sites; Zinc finger (ZnF) and leucine rich motifs are also indicated. The
numbers specify the number of amino acids
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conclusions. The various strategies used to delete HDAC2
might explain—at least in part—these different findings.
The Hdac2 KO was performed by Montgomery and col-
leagues [17] using a conditionally targeted Hdac2 locus
which leads to deletion of exons 2, 3, and 4, thus com-
promising part of the (oligo) hetero-/homodimerization
domain and the catalytic domain required for enzymatic
activity. This strategy generated a mutant Hdac2 allele
with two splice variants, an all-in-frame transcript and an
out-of-frame transcript. In mice carrying this modified
allele, no HDAC2 protein was detectable. Although born at
the expected Mendelian ratio, these Hdac2-deficient mice
died within 24 h after birth [17]. Detailed histological
analysis of these Hdac2-deficient neonates revealed mor-
phological changes of the heart [17]. The complete
lethality of these HADC2-null mice contrasts with the
findings in several other studies reporting that the majority
of Hdac2-deficient mice were partially viable with a tran-
sient growth retardation phenotype. Deletion of HDAC2
using a gene-trap insertion led to partial embryonic
lethality, with about 50% death within the first months [18,
19]. In this case, the random insertion of LacZ into the
Hdac2 locus exon 9 generated an enzymatically inactive,
in-frame HDAC2–LacZ fusion protein which lacks the
C-terminus [19]. Finally, similar results were obtained with
a conditional gene targeting of Hdac2 exons 5 and 6 by
Guan and colleagues and of Hdac2 exon 6 in our labora-
tory; these alleles affected the histone deacetylase domain
and also led to partial perinatal lethality and reduced body
size [15, 20]. In the detailed study from Trivedi and col-
leagues [18], the postnatal mutant Hdac2 mice had smaller
hearts than wild-type mice and a thickened myocardium at
day 8 after birth. In Hdac2-deficient hearts, the gene
encoding inositol polyphosphate-5-phosphatase f (Inpp5f)
was upregulated, resulting in constitutive activation of
glycogen synthase kinase 3b (GSK3b) and protection from
hypertrophy [18]. Chemical inhibition of activated Gsk3b
caused these Hdac2-deficient mice to become sensitive to
hypertrophic stimulation. In contrast, transgenic mice
overexpressing HDAC2 displayed increased hypertrophy
coupled to inactivated Gsk3b [18]. This suggested that
HDAC2 and GSK3b are components of a regulatory
pathway involved in cardiac hypertrophic response. The
KO studies of HDAC1 and 2 demonstrated specific and
distinct roles of these two enzymes in mouse embryogen-
esis and development. Global Hdac3 KO led to gastrulation
defects and death of the embryo prior to E9.5 [21, 22]. In
contrast, HDAC8 deletion led to perinatal lethality due to
skull instability [23].
Tissue-specific analysis of class I HDACs
To overcome the early embryonic lethality associated with
class I HDAC ablation, conditional alleles in combination
with various cre-expressing strains were generated. These
strategies allowed the investigation of the function of class
I HDACs in specific tissues. In addition to KO experi-
ments, several ex vivo studies based on cultured cell lines
were conducted to address the mechanisms involved in
class I HDACs functions.
HDAC1 and 2
Role of HDAC1 and 2 in cell cycle regulation and DNA
damage control
HDAC1 and 2 are usually co-expressed and often show
redundancy in their function in many adult tissues and
cultured cell lines [15, 24, 25]. However, several studies
reported specific functions of these two homologues during
development. It is important to mention that, in several
cellular systems, deletion of HDAC1 leads to an increased
level of HDAC2 protein and vice versa, without
Sin3
Mi2 / NuRD complex
CoRESTHDAC2p80
LSD1
Znf217
HDAC1
CoREST complex
TBL1
N-CoR/SMRT
GPS2
N-CoR/SMRT  complex
HDAC1
RbAp46
SAP30 SAP18
Sin3 complex
RbAp48
HDAC2
Mi2HDAC1
RbAp46
MTA2 MBD2/3
RbAp48
A B
C D
Sox like
protein
P66
LSD1
HDAC2
TBLR1
HDAC3
KDM4A 
Fig. 2 Class I HDACs complexes and their components. a The Sin3
complex contains six subunits: the transcriptional co-repressor Sin3,
two Sin3 associated proteins (SAP18 and 30) and two Rb associated
proteins (RbAp46 and 48). HDAC1 and 2 form the catalytic core of
this complex [115, 116]. b The Mi2/NuRD complex shares the dimers
HDAC1 and 2 and RbAP46 and 48 with the Sin3 complex. In addition
this complex contains the chromatin remodeler Mi2, the methyl CpG
binding domain protein MBD2 or MBD3, the lysine-specific
demethylase LSD1 [117], the transcriptional repressor p66 and
MTA2 (a member of metastasis associated family) [118–120]. c The
CoREST complex contains the co-repressor CoREST, the lysine-
specific demethylase LSD1, the Kruppel-like zinc-finger protein
Znf217, the Sox-like protein and p80 [121]. d The N-CoR/SMRT
complex contains N-CoR (Nuclear receptor CoRepressor) or SMRT
(Silencing Mediator for Retinoid and Thyroid receptor), TBL1
(transducin b-like 1), TBLR1 (TBL related 1), GPS2 (G-protein
pathway suppressor 2), the lysine-specific demethylase KDM4A
[122] and HDAC3 ([123]; for review, see [12]). HDAC complexes are
reviewed in [4, 13]
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Table 1 List of phenotypes observed in mice
Target organ/
tissue
Cre driver Observation/phenotype Reference
HDAC1
and 2
Germline Global H1 KO lethal E9.5–10.5 due to proliferation defect and dev.
retardation
[16, 17];
Yamaguchi, p.c.
Germline Global H1 KO combined with p21 KO no rescue possible [14]
Germline Global H2 KO neonates die shortly after birth (24 h), due to
cardiac defects
[17]
Germline Global H2 KO 50% perinatal lethal (1 mo), smaller in size,
hypertrophy in the heart, 50% survive until adulthood
[15, 18–20]
T cell dev. Cd4-cre H1 KO leads to increased proliferation and increased
inflammation response in an allergic airway model
[54]
Hippocampal/
Neurons
Transfection H1 OE protects neurons from DNA damage and
neurotoxicity
[49]
Synapse dev. Lentiviral infection H2 KO leads to reduced synaptic activity; DKO increased
synaptic activity and synapse numbers, involved in
synaptic maturation
[51]
Neurons Nestin-cre H2 KO leads to enhanced learning and memory formation;
H2 OE leads to impairment, rescue with HDACis
possible
[20]
Brain Global and
GLAST::CreERT2/Z/EG
H2 KO leads to differentiation block and apoptosis during
adult neurogenesis
[47]
CNS GFAP-cre DKO in neuronal progenitors increases proliferation and
block in diff., alters lineage-specificity
[45]
Oligodendrocyte
diff.
Olig1-cre DKO mice die postnatal 2 w, required for oligodendrocyte
specification and diff.
[46]
PNS Dhh-cre DKO in PNS leads to apoptosis of Schwann cells and
abrogated myelination
[42, 48]
Heart MHC-cre DKO is neonatal lethal due to cardiac defects [17]
Epidermis KRT14-cre DKO leads to impaired epidermal and hair follicle
development, perinatal lethal, block in cell cycle
[25]
Liver Mx-cre DKO in hematoptiesis alters erythrocyte–megakaryocyte
diff., increase in apoptosis
[24]
B-cell dev. Mb1-cre or
CD23-cre
DKO impairs B-cell diff., cell cyle G1 blocks and increased
apoptosis (p21 not altered, own observation)
[15]
HDAC3 Germline Global lethal prior to E9.5 due to gastrulation defects [22, 58]
Liver Albumin cre Long term study leads to genomic instability and to
hepatocellular carcinoma (mean survival 10 mos)
[58]
Liver Albumin cre Leads to increased liver size, metabolic changes
carbohydrate and lipid imbalance
[59]
Heart MHC-cre Cardiac-specific loss leads to lethality by 3–4 mos, due to
cardiac defects, hypertrophy and deregulated metabolism
[22]
Heart Myocyte-specific OE Heart defects without hypertrophy [61]
Skeletal dev. Osterix-cre Causes bone formation defects, reduced volume and cell
number
[62]
Brain Genetic and
pharmacological
approach
Enhanced long-term memory formation, [64]
HDAC8 Germline Global Perinatal lethal, due to skull instability (craniofacial
defects)
[23]
Neural crest Wnt1-cre Phenocopied the global deletion, skull dysmorphism [23]
Knockout (KO) and overexpression (OE) of class I HDACs
H1 HDAC1, H2 HDAC2, DKO double knockout HDAC1 and 2, h hour, w week, mo month, dev. development, diff. differentiation, p.c. personal
communication, PNS peripheral nervous system, CNS central nervous system
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corresponding change of the mRNA level [15, 16, 24, 26].
This compensatory effect suggests common mechanisms
regulating HDAC1 and 2 protein levels and reinforces the
idea that these two proteins are implicated in shared regu-
latory pathways. Several studies have demonstrated that
HDAC1 and 2 play a crucial role in cell cycle regulation.
Hdac1-deficient embryonic stem cells show reduced pro-
liferation, which correlates with decreased cyclin A and
cyclin E-associated kinase activities and elevated levels of
the cyclin-dependent kinase inhibitors p21 and p27; this is
correlated to hyperacetylation of histone H3 and H4 on the
promoters of these genes, suggesting that these promoters
may be direct targets of HDAC1 in ES cells [16]. Indeed,
chromatin immunoprecipitation (ChIP) experiments showed
that HDAC1 binds to the p21 promoter in ES cells. Impor-
tantly, ablation of p21 in Hdac1-deficient ES cells rescues
the proliferation defect; however, this does not overcome the
embryonic developmental block, indicating that this phe-
notype is not only due to a proliferation defect [14].
In primary mouse embryonic fibroblasts (MEFs), dele-
tion of HDAC1 reduces proliferation and causes a partial
G1/S arrest, while deletion of HDAC2 has little or no effect
on proliferation [15]. By contrast, combined deletion of
both enzymes led to strong cell cycle arrest at the G1 phase
accompanied by concomitant upregulation of p21 and p57,
followed by apoptosis. This upregulation is direct, since
HDAC1 and 2 bind to the p21 and p57 promoters and can
repress their transcription. Importantly, siRNA-mediated
knockdown of these two genes partially rescued the pro-
liferation defect [15]. In another study, it was also shown
that deletion of HDAC1 and 2 or inactivation of their
deacetylase activity in primary or oncogenic-transformed
fibroblasts led to senescence-like G1 cell cycle arrest
accompanied by upregulation of p21 and p53. Strikingly, in
this case, ablation by siRNA of these two proteins did not
rescue the proliferation defect, indicating that HDAC1 and
2 also regulate p53–p21 independent pathways critical for
maintaining cell cycle progression [24].
SiRNA-mediated knockdown of HDAC1 and 2 in var-
ious human tumor cells indicated that the requirement for
HDAC1 and/or HDAC2 for cell cycle progression may be
cell type-dependent [26]. Indeed, knockdown of HDAC1
only or HDAC1 plus HDAC2 in U2OS (osteosarcoma cell
line) and MCF7 (mammary carcinoma cell line) cells led to
cell cycle arrest in the G1 phase or apoptosis during the G2/
M transition. Conversely, this phenotype was not observed
in the non-tumorigenic epithelial mammary gland cell line
MCF10A. Strikingly, deletion of HDAC1 alone or HDAC1
plus HDAC2 led to p21 upregulation only in U2OS cells.
Unlike the phenotype due to HDAC1 deletion, HDAC2
knockdown showed no effect on cell proliferation in the
three analyzed cell lines [26]. Although the knockdown
efficiency can vary between cell lines and this variability
can influence the outcome of this study, these results sug-
gest a cell-specific role of HDAC1 and 2 in cell cycle
regulation.
HDAC1 and 2 also play a role in the DNA damage
response. Depletion of HDAC1 and 2 causes hypersensi-
tivity to the double-strand breaks (DSB)-inducing agents
ionizing radiation and phleomycin [27]. HDAC1 and 2
were found to localize to the sites of DNA damage and are
responsible for deacetylation of H3K56ac, which is
believed to play a role in DNA damage response [28]. As
repair of DNA lesions constitutes an important cell cycle
check point, this suggests that HDAC1 and 2 can also
affect cell cycle progression via their action on DNA
damage control.
Recruitment of HDAC1 and 2 to cell cycle regulator
genes by various transcription factors
The majority of studies that addressed the role of HDAC1
and 2 in cell cycle regulation demonstrated that this reg-
ulation occurs at least partially via direct transcriptional
repression of cell cycle regulators such as p21, p27, and
p57. Since HDACs lack a DNA binding domain, a central
question is how are HDACs complexes recruited to the
promoters/genes they regulate? The transcription factor
SP1 has been found to be required for HDAC1-mediated
transcriptional repression of the thymidine kinase promoter
[29]. HDAC1 binds directly to the C-terminus of Sp1,
which is also involved in the interaction with p53 [29, 30].
It was shown that p53 and HDAC1 are antagonistic regu-
lators of p21: p53 cooperates with Sp1 to activate the p21
promoter, whereas HDAC1 counteracts p53 action by
repressing p21 transcription via its interaction with Sp1
(Fig. 3). Induction of p53 in response to DNA-damaging
agents resulted in the formation of a p53–Sp1 complex and
dissociation of the HDAC1–Sp1 complex. Chromatin
immunoprecipitation (ChIP) experiments showed that
HDAC1 is recruited to the p21 promoter in proliferating
cells, while genotoxic stress leads to recruitment of p53,
reduced binding of HDAC1, and hyperacetylation of core
histones at the p21 promoter [30]. These data indicate that
Sp1 may recruit HDAC1 to the p21 promoter to repress its
activity in proliferating cells. Other critical transcription
factors were shown to require HDAC activity to exert their
functions: The retinoblastoma protein (pRb) regulates the
G1/S transition by repressing a subset of genes that are
controlled by the E2F family of transcription factors [31,
32]. The complex formed by HDAC1, pRb, and E2F
represses transcription of E2F target genes such as cyclin E
[33–35]. It was also shown that the tumor suppressor and
chromatin modulator matrix attachment region (MAR)
binding protein (SMAR1) recruits the Sin3/HDAC1 com-
plex to the cyclin D1 promoter, leading to deacetylation of
HDACs in differentiation and cell cycle 2177
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histone residues H3K9 and H4K8 at that locus and reduced
expression [36].
In melanoma cells, the T-box transcription factor Tbx2
plays an important role in maintaining proliferation and
suppressing senescence. Tbx2 represses p21 expression by
recruiting HDAC1 to its promoter (Fig. 3). Expression of a
dominant-negative Tbx2 leads to displacement of HDAC1
and upregulation of p21 expression which correlate with
the induction of replicative senescence in melanoma cells
[37]. In mice, combined deletion of Hdac1 and 2 in the
ectoderm led to perinatal lethality due to defects in epi-
dermal proliferation and differentiation accompanied by
repression of p21, p16, and 14-3-3r. The repression of
these genes is mediated by the key ectodermal transcription
factor p63 and requires HDAC1 and 2. This suggests that
p63 recruits HDAC1 and 2 to these genes to repress their
transcription (Fig. 3) [25]. In rat smooth muscle cells
(SMC), knockdown of either Hdac1, 2, or 3 prevents
mitogen-induced SMC proliferation. Reduction of SMC
proliferation by HDACs depletion involves a growth arrest
in the G1 phase of the cell cycle which correlates with
inhibition of pRB phosphorylation, as well as transcrip-
tional and post-transcriptional regulation of p21 and p27
[38].
In addition to the role of HDACs in regulating gene
expression via histones deacetylation, it has been reported
that they can also impact on gene expression by deacety-
lating other non-histone proteins such as transcription
factors. In vitro studies suggest that p53 activity is modu-
lated in an HDAC1-dependent manner through removal of
acetyl groups from its C-terminal lysine residues and
ensuing modulation of its DNA-binding affinity [39–41]. It
has also been shown that HDAC1 and 2 suppress p53
hyperacetylation in embryonic epidermis (Fig. 3) [25].
HDAC1 and 2 also target other transcription factors such as
NFjB [42] (see below), and the myogenic differentiation
factors MyoD [43], E2F1 [44], and several others (for
review, see [2]).
MEFs
Melanoma cells Keratinocytes
Hela cells MCF7 cells
Sp1
p21HDAC1&2
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Fig. 3 HDAC1- and 2-mediated repression of cell cycle regulators.
a Recruitment of HDAC1 and 2 complexes to their target genes by
various transcription factors in different cellular systems. Transcrip-
tion factors (TF) are schematized as gray circles and nucleosomes as
yellow circles, cellular systems and target promoters are indicated;
red inhibition symbols indicate direct repression by deacetylation of
histones at the indicated loci. b Schematic representation of indirect
repression of the p21 promoter by HADCs via p53 deacetylation
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HDAC1 and 2 function in the nervous system
Mice lacking both HDAC1 and 2 in the central nervous
system (CNS) displayed major aberration of cortical, hip-
pocampal, and cerebellar development, and die postnatally
by day 7 [45]. In addition, differentiation of neuronal
precursors into neurons requires the presence of either
HDAC1 or HDAC2, strongly suggesting functional
redundancy [45]. HDAC1 and 2 are also required for oli-
godendrocyte specification and differentiation, where they
play a role in stabilizing b-catenin and thereby activating
Wnt signaling [46]. Mice lacking HDAC1 and 2 in oligo-
dendrocyte lineage developed severe tremors and died
postnatally within 2 weeks [46]. Interestingly, comparing
neurogenesis during development and adulthood, HDAC2
is found to be essential for appropriate differentiation and
survival of adult generated neurons, however unnecessary
during development [47]. Loss of HDAC2 in adult neurons
leads to an aberrant maintenance of Sox2 expression and an
increased rate of progenitor proliferation [47].
In the peripheral nervous system (PNS), ablation of
HDAC1 and 2 in the Schwann cell lineage results in severe
myelination defects in sciatic nerves accompanied by
altered development of Schwann cells [42, 48]. Two dis-
tinct mechanisms have been proposed to explain this
phenotype. First, it was observed that, in the absence of
both HDAC1 and 2 in Schwann cells, the NF-jB p65
subunit becomes hyperacetylated, leading to the deregula-
tion of NFjB-dependent genes controlling Schwann cell
differentiation. This indicates that HDAC1 and 2 regulate
NF-jB function by deacetylating its p65 subunit [42].
Second, it was demonstrated that, in Schwann cells,
HDAC1 and 2 also exert specific primary functions:
HDAC2 activates the transcriptional program of myelina-
tion in synergy with Sox10, whereas HDAC1 controls
Schwann cell survival by regulating the level of b-catenin
expression [48]. Other specific functions for HDAC1 and 2
have been observed in the neuronal system. HDAC1
activity plays a clear role in neuroprotection, while the loss
of HDAC2 enhances memory formation [20, 49]. CK-p25
is a mouse model of rapid neurodegeneration, mimicking
an Alzheimer’s-like disease. p25 is a truncated form of
p35, a regulatory subunit associated with cyclin-dependent
kinase 5 (Cdk5) [50]. CK-p25 mice show aberrant cell-
cycle and double-strand DNA breaks leading to neurotox-
icity, due to the inhibition of HDAC1 activity directly
mediated by p25/Cdk5 induction [49]. Importantly, in these
mice, the neurotoxicity and DNA damage could be rescued
by HDAC1 overexpression [49]. Likewise, HDAC1 gain-
of-function protected neurons against ischemia-induced
DNA damage and neurotoxicity in a stroke model in vivo
[49]. In contrast, mice with a neuron-specific HDAC2
deletion exhibited enhanced learning and memory
formation, similar to chronic treatment with HDAC
inhibitors (HDACis) [20]. HDAC2 interacts with CoREST
which in turn negatively regulates neurogenesis and
memory. In addition, HDAC2 was found to bind to the
promoter regions of genes involved in synaptic plasticity
and neuronal activity [20]. It has also been shown that
neuron-specific overexpression of HDAC2, but not of
HDAC1, resulted in memory impairment and in decreased
synaptic plasticity, which could be rescued by HDACis
[20]. Using primary dissociated hippocampal neurons from
newborns as an ex vivo model of synapse development,
Akhtar and colleagues [51] observed complementary
functions of HDAC1 and 2 in synapse development. This
suggests that HDAC1 and 2 act as a developmental switch
to control maturation of synapses and function.
HDAC1 and 2 function in other systems
Cardiac-specific KO of either Hdac1 or Hdac2 had no
apparent effect on cardiac function, indicating functional
redundancy. By contrast, combined loss of both genes leads
to cardiomyopathy, arrhythmias, and postnatal lethality by
day 14, accompanied by deregulation of genes encoding
skeletal muscle-specific proteins and calcium channels [17].
Recently, GATA binding protein 4 (GATA4) was found as a
novel non-histone target of HDAC2 [52]. HDAC2 directly
interacts with GATA4, and this interaction is stabilized by a
small HOP homeobox protein (Hopx) [52]. Together, they
regulate cardiac myocyte proliferation during embryonic
development. Global ablation of HDAC2 and Hopx leads to
cardiac developmental defects, increased cardiac myocyte
proliferation and perinatal lethality. Moreover, the dual loss
leads to GATA4 hyperacetylation and repression of
GATA4-dependent cell cycle genes [52].
HDAC1 and 2 also play an important role in epidermis
development. In this system, loss of either Hdac1 or Hdac2
showed no apparent phenotype [25]. In contrast, in the
absence of both enzymes, embryos died perinatally with
multiple ectodermal defects. In addition to having an undif-
ferentiated epidermis, these embryos also failed to develop
hair follicles, tongue papillae, eyelids, and teeth. This epi-
dermal phenotype is similar to the loss of the epidermal master
regulator p63. Genes that are normally repressed by p63 were
upregulated in Hdac-deficient undifferentiated keratinocytes,
in particular genes involved in cell cycle regulation and epi-
dermal development [25]. These results suggest that p63 exert
its repressive function via HDAC1 and 2.
It has also been reported recently that HDAC1 and 2 act
redundantly to control adipogenesis: simultaneous deletion
of these two enzymes in MEFs leads to reduced lipid
accumulation and blocks the in vitro differentiation of
MEFs to adipocytes. By contrast, deletion of HDAC1 or 2
only does not affect adipogenesis [53].
HDACs in differentiation and cell cycle 2179
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In the hematopoietic system, deletion of either HDAC1
or HDAC2 has no striking effect, while dual inactivation of
both enzymes leads to apoptosis of megakaryocytes and
thrombocytopenia (decrease of platelets in blood) [24].
Similar results were obtained in the B cell lineage. It was
found that, in the absence of HDAC1 or 2, B cell devel-
opment proceeds normally, indicating functional
redundancy between HDAC1 and 2. By contrast, dual
inactivation of Hdac1 and 2 in early B cell progenitors led
to a dramatic block in B cell development at the pre-B cell
stage, accompanied by G1 cell cycle arrest and apoptosis
[15]. Additionally, while one allele of Hdac2 in the absence
of HDAC1 is not sufficient to rescue proper B cell devel-
opment, one Hdac1 allele in the absence of HDAC2 is able
to restore B cell differentiation. This haplo-insufficiency of
HDAC2 indicates that HDAC1 and 2 have some non-
redundant functions (Yamaguchi et al., unpublished data).
In contrast to other systems, conditional deletion of only
HDAC1 in T cells results in increased proliferation [54]. In
an in vivo allergic airway inflammation model, the T cell-
specific loss of HDAC1 leads to an increased inflammatory
response which correlates with enhanced Th2 cytokine
production and cellular proliferation [54]. This indicates
that the influence of HDACs on proliferation is cell type-
specific and depends on the physiological environment.
HDAC3
Role of HDAC3 in cell cycle regulation and DNA
damage control
HDAC3 is an attractive target for cancer research due to
increasing evidence supporting its role in cell cycle pro-
gression and DNA damage control [21, 55]. HDAC3 has
been found to be required for normal mitotic progression
and maximal phosphorylation of H3S10 (phosphorylation
of H3S10 is an evolutionary conserved mitotic event [56])
[55]. HDAC3 forms a complex with A-Kinase-Anchoring
Proteins AKAP95 and HA95, which are targeted to mitotic
chromosomes [55]. Deacetylation of H3 in mitosis requires
AKAP95/HA95 and HDAC3 and provides a hypoacety-
lated H3 tail that is the preferred substrate for Aurora B
kinase that phosphorylates H3S10 [55]. These observations
were supported by conditional inactivation of HDAC3 in
MEFs [21]. The loss of HDAC3 also led to a delay in cell
cycle progression during S phase accompanied by
increasing DNA damage and apoptosis [21]. However, no
mitotic alterations and phosphorylation changes of
H3Ser10 were observed in these Hdac3-deficient cells [21].
In addition, DNA damage observed in interphase MEFs
correlated with impaired DNA double-strand break repair.
Interestingly, arrested or quiescent MEFs lacking HDAC3
were protected from DNA damage. These results might
explain the findings that HDACis preferentially influence
cancer cells or highly proliferating cells rather than primary
or quiescent cells [57]. In an additional study, Bhaskara
and colleagues showed that deletion of HDAC3 in MEFs
led to impaired DNA repair, reduced chromatin compac-
tion and heterochromatin content. This correlates with an
increase in histone H3K9, H3K14, H4K5, and H4K12
acetylation in late S phase of the cell cycle. Importantly,
histone marks such as H4K5ac and H4K12ac, which are
commonly associated with histone deposition onto newly
synthesized DNA, were maintained in quiescent Hdac3-
deficient cells [58]. In the same study, it was shown that
liver-specific deletion of Hdac3 led to hepatocellular car-
cinoma accompanied by downregulation of NCOR1 [58].
These data indicate the importance of the HDAC3/NCOR
axis in liver function; however, the exact role of these
factors remains to be further elucidated [58].
HDAC3 function in other systems
Liver-specific loss of HDAC3 results in aberrant lipid and
cholesterol biosynthesis shortly after birth. Later, the liver
displays disturbed lipid and cholesterol homeostasis,
leading to an accumulation of lipids and a decrease in
glycogen storage [59]. This phenotype is due to the dere-
pression of a gene program that is usually under the control
of nuclear hormone receptors [59]. A recent study unrav-
eled a link between HDAC3 and the circadian rhythm in
the mouse liver [60]. Importantly, the circadian nuclear
receptor Rev-erba recruits HDAC3 to genes regulating
lipid metabolism [60]. Deletion of HDAC3 or Rev-erba in
mouse liver led to hepatic steatosis and deregulated gene
expression, correlating with changes in histone acetylation.
These findings indicate that genomic recruitment of
HDAC3 by Rev-erba directs a circadian rhythm of histone
acetylation and gene expression that is required for normal
hepatic lipid homeostasis [60].
In the cardiac system, loss of HDAC3 in cardiomyocytes
was lethal within 3–4 months after birth [22]. Massive car-
diac hypertrophy and derepression of genes that control
fatty-acid uptake and metabolism were observed in mice
lacking HDAC3, and expression of p21 was upregulated in
Hdac3-deficient hearts [22]. Furthermore, myocyte-specific
overexpression of HDAC3 also resulted in heart defects and
cardiomyocyte hyperplasia, leading to increased thickness of
the myocardium [22]. In contrast to the HDAC2 overex-
pression model mentioned above, the increased thickness of
the myocardium was not associated with hypertrophy [61].
Therefore, HDAC3 is another important regulator of cardiac
myocyte proliferation during cardiac development. Hdac3-
deficient mice were smaller and had a reduced life span, as
compared to wild-type animals. HDAC3 ablation caused
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severe defects in bone formation and increased bone marrow
adipogenesis [62]. HDAC3 was shown to be associated to an
orphan nuclear receptor TLX and to mediate neural stem cell
proliferation and self-renewal by transcriptional repression
[63]. Ablation of HDAC3 leads to increased expression of
the p21 and phosphatase and tensin homologue (pten) genes
and inhibition of neuronal stem cell proliferation [63].
Similar to HDAC2, specific HDAC3 inactivation in the
dorsal hippocampus leads to enhanced long-term memory
and elevated expression of nuclear receptor subfamily 4,
group A, member 2 (Nr4a2), a gene associated with long-
term memory formation [64]. Recently, the loss of HDAC3
was analyzed during embryonic cardiac and neural crest
development [65]. Ablation of HDAC3 led to a block in
smooth muscle differentiation and downregulation of the
Notch ligand Jagged1 [65]. These reports demonstrate the
critical role of HDAC3 in the regulation of specific factors
that are important for lineage differentiation during devel-
opment. Recently, HDAC3 was found to also be required for
gene induction by transforming growth factor beta (TGFb)
via activation (phosphorylation) of PI3K (phosphoinositide
3-kinase) and ERK (extracellular signal regulated kinase).
The exact mechanism by which HDAC3 affects these path-
ways needs to be further investigated [66].
HDAC8
HDAC8 has been described as playing an important role in
proliferation of sympathetic neuroblastoma cells [67]. High
HDAC8 expression levels correlate with advanced stage
childhood neuroblastoma, clinical and genetic risk factors,
and poor long-term survival. HDAC8 ablation in neuroblas-
toma cells induces morphologic changes, inhibits
proliferation and colony formation, and causes cell cycle
arrest [67]. Despite these facts, little is known about the role of
HDAC8 in the CNS. Additional insights come from the role of
HDAC8 as a regulator of cAMP response element-binding
(CREB)-dependent gene expression [68]. CREB target genes
are essential in diverse processes such as glucose metabolism,
cell survival, and neuronal plasticity (for review, see [69]). It
has been reported that HDAC8, like HDAC1, promotes the
dephosphorylation of CREB at serine 133 via a stable inter-
action with protein phosphatase 1 (PP1), and therefore inhibits
CREBs transcriptional activity [55, 57].
HDACs in the clinic: use of HDACs inhibitors to treat
disease
As discussed above, recent genetic studies on HDACs have
begun to identify specific and redundant functions for
many of these enzymes, but further analysis will be needed
to uncover the full spectrum of their physiological roles.
Initial studies on HDACs relied heavily on small molecules
inhibitors (HDACis), and described early on that in vitro
proliferation of tumor cell lines is impaired by HDAC
inhibition [70]. In addition, several HDACs were found to
be deregulated (overexpressed) in various kinds of tumors
or cancer cell lines, suggesting that epigenetic (de)regula-
tion could play a role in cancer [71–74]. Together, these
findings sparked a very intense research into the possible
use of HDACis for therapeutic purposes. Although the
research on the therapeutic potential of HDACis was ini-
tially concentrated in oncology, other areas such as
neurodegeneration or autoimmunity have recently been
investigated. Because of the high medical relevance of
these observations, we will review here some of the
important advances in HDACis and their use.
HDACis can be grouped into four main structural clas-
ses, with a growing list of novel compounds: first, the
hydroxamic acids [e.g. trichostatin A (TSA), Suberoylani-
lide Hydroxamic Acid (SAHA, Vorinostat, Zolinza), and
LBH589 (Panobinostat)]; second, the short chain carbox-
ylic acids [Phenylbutyrate and Valproic acid (VPA)]; third,
the benzamides [MS-275 (Entinostat)]; and fourth, the
cyclic tetrapeptides [Romidepsin (FK-228 2, Istodax)].
They all target the deacetylase enzymatic activity of
HDACs by binding the active site and competing with the
Zn2? ion in the active pocket [75, 76]. As a result, the
substrate pocket is blocked and the enzyme inactivated,
thereby causing an increase in histones acetylation (for
review, see [77]). HDACis also affect other biological
processes than chromatin dynamics and increase the acet-
ylation level of non-histone proteins, such as tubulin and
others [78–80]. A common effect of HDACis in cancer
cells is the induction of the cell cycle regulator p21 [81].
This is often conducted in a p53-independent manner and is
at the core of the proliferation-inhibiting effects of HDA-
Cis in cancer cells (for review, see [82]). Many pan-
HDACis induce cell cycle arrest and inhibit proliferation,
leading to induction of differentiation, growth arrest, and
apoptosis of transformed cells, by downregulating a com-
mon set of genes [83, 84]. These effects are dose- and
inhibitor-dependent. Several HDACis have been investi-
gated in clinical trials for their potential as anticancer drugs
[82, 85]. The first identified and most prominent HDACi is
the naturally occurring antifungal antibiotic TSA [70]. TSA
is one of the most potent HDACis, exhibiting EC50 values
in low nanomolar range against HDAC1, 2, 4, 6, 7, and 9,
but less efficient against HDAC8 [86]. Although TSA
appeared very promising in preclinical investigations, it
was not suitable for clinical use due to unfavorable phar-
macological side effects (for review, see [87]).
To date, two HDACis have been approved as anticancer
drug in humans: Vorinostat (SAHA, Zolinza; Merck
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Research Laboratories) and Romidepsin (FK-228 2, Isto-
dax; Gloucester Pharmaceuticals). SAHA has been
approved since 2006 as a therapeutic approach in patients
with progressive, persistent, or recurrent cutaneous T cell
lymphoma (CTCL) after one or more lines of chemother-
apy [88–92]. SAHA efficiently inhibits HDAC1, 2, 3, 4, 6,
7, and 9, similar to TSA, but 5- to 30-fold less potent [86].
This classic pan-HDACi can induce apoptosis as well as
autophagy in cancer cells. Romidepsin (FK-228 2), one of
the more selective inhibitors, has also been approved since
2009 to treat CTCL [93–96]. It belongs to the cyclic pep-
tides that strongly inhibit HDAC1 and 2, and inhibits
HDAC class II enzymes at higher concentrations [97–99].
The fact that Romidepsin, which preferentially inhibits
HDAC1 and 2, is also effective in CTCL may suggest that
this disease is particularly dependent on the function of
these two enzymes.
The major side effects associated with HDACis are gas-
trointestinal symptoms, bone marrow suppression [100],
cardiac toxicity [101], thrombocytopenia, neutropenia,
diarrhea, nausea, vomiting, and fatigue [6, 102]. Although
these side effects should be taken into consideration, it is
important to mention that HDACis are well tolerated in the
majority of patients compared to other anticancer treatments.
Several HDACis have already demonstrated preclinical
efficacy as monotherapy as well as in combination with other
anticancer agents (for review, see [87]). Moreover, an
exciting finding is the observation that HDACis adminis-
tered at low concentrations are efficacious for treating a
range of diseases that are not related to cancer. For example,
HDACis exhibit anti-inflammatory properties due to a
reduction of cytokine production as well as inhibition of
cytokine effects (for reviews, see [103], [104]). Furthermore,
experiments in mouse models have shown beneficial effects
of HDACis in neurodegenerative conditions and autoim-
munity and several clinical trials are currently underway in
these areas (for reviews, see [104, 105]).
It is likely that a specific HDACi will have clinical
benefits only in a specific tumor type and/or in a subset of
patients. For future treatment and effective selection of the
‘‘right’’ HDACis for a given therapy, the availability of
predictive and prognostic biomarkers will be crucial.
Recently, the ubiquitin-like fusion protein HR23B (RAD23
homolog B of S. cerevisiae) has been described as a pos-
sible candidate cancer biomarker in CTCL patients [106,
107]. Yet, the few identified HDACis biomarkers known so
far do not reflect tumor response or correlate to the dosage
of the HDACis needed [108], and more work is required to
make progress in this important area.
Recently, while modeling the acute response to various
anti-cancer agents in drug-sensitive human tumor cell lines,
a small drug-tolerant cancer cell subpopulation has been
described [109]. This cell subpopulation emerges de novo
and is reversibly drug-tolerant, indicating that its resistance
to drug treatment is not due to mutation but rather to
changes in gene expression [109]. Treatment of these cells
with HDACis, such as TSA, selectively ablates them,
presumably by influencing the chromatin. This correlates
with an induction of DNA damage response via c-H2AX
[109]. Moreover, in these in vitro experiments, it was
shown that constant treatment with HDACis prevents the
development of drug tolerance in cancer cells [109]. These
observations indicate that HDACis, or other chromatin
modifying agents, may have a general impact on the
emergence of drug-tolerant cells and, thus, may be useful
in combination with other drug treatments.
Pan versus specific HDAC inhibitors and their benefits
Class I selective HDACis display similar toxicity as pan-
HDACis. This suggests that the inhibition of HDAC1, 2,
and 3 are the main reasons for most of the observed side
effects. Fatigue syndrome, gastrointestinal difficulties, and
cardiac toxicity are all observed using class I selective
inhibitors (MS-275 or Depsipeptide) [110, 111] or pan-
HDACis (Vorinostat) [89]. This is perhaps not surprising
since HDAC1, 2, and 3 have been reported to hold key
functions in various pathways evidenced in knockout
studies, for example cell proliferation arrest and apoptosis,
and metabolic and cardiac abnormalities [16, 17, 59].
Importantly, it has been shown that class I and class II or
individual HDACs are often differentially expressed in
human cancers; for example, HDAC1 or 2 expression is
increased in gastric cancer [71, 72]. In contrast, in prostate
cancer, only HDAC1 is upregulated [73], and in lung
cancer, only HDAC3 [74]. Recently, HDAC8 was identi-
fied to be a crucial regulator of tumorigenesis in
neuroblastoma cells [67]. APCmin (Min, multiple intestinal
neoplasia) mice carry a point mutation in the Adenomatous
polyposis coli (APC) gene and are highly susceptible to
spontaneous intestinal adenoma formation [112, 113].
Elevated HDAC2 levels were observed in tumors induced
by APC mutations [114], and it was reported that the loss
of HDAC2 in APCmin mice leads to 10% decreased tumor
rates in the gut [19]. Moreover these genetic approaches
gave comparable results to studies conducted with HDA-
Cis. Recent studies of tumor cell survival in vitro indicate
that dual loss of HDAC1 and 2 mimics the reported effects
of HDACis in cancer cells [7].
Conclusion and perspectives
The recent advances in the study of HDACs have shown
that these enzymes exert a large variety of functions by
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deacetylating histones as well as non-histone proteins.
Class I HDACs were found to be important for specific
functions in several tissues where they are involved in the
regulation of differentiation, proliferation, cell cycle pro-
gression, and apoptosis. It was demonstrated that HDAC1
and 2 directly control the expression of genes involved in
cell cycle regulation such as p21. It has also been shown
that HDAC1, 2, and 3 play a role in DNA damage
response, and subsequently can be important for DNA
replication and cell cycle progression. Some of the
important pathways have been identified, but many of the
chromatin targets of HDACs remain to be identified in
different cellular settings. The transcription factors or
mechanisms recruiting HDAC complexes have so far only
been described in few cases and further analysis is nee-
ded. Genome-wide mapping of HDACs and their partners
will address this issue by defining direct target genes and
will allow the distinguishing of common from specific
targets.
The increasing number of acetylated non-histone pro-
teins suggests an important role for HDACs in the
regulation of cellular processes beyond chromatin and gene
expression. Acetylome analyses in cells lacking specific
HDACs will be a powerful tool to identify specific sub-
strates and define the pathways in which these enzymes are
involved. As highlighted above, class I HDACs are
excellent therapeutic candidates for anticancer treatment. A
better understanding of the role of individual HDACs, in
normal physiology as well as in various pathological set-
tings, will give a framework for the development of more
specific inhibitors. While having selective inhibitors should
be useful to reduce side effects, in particular for non-cancer
applications, it may be necessary to target more than one
HDAC to achieve clinical benefits in some cancer settings.
Further genetic studies in model systems will be needed to
address this issue.
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